(Q42181572)

18 October 2017

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. (English)

1 reference

18 October 2017

8

Tania Kümpfel

1 reference

18 October 2017

19

Hans-Peter Hartung

1 reference

18 October 2017

23

Bernd C Kieseier

1 reference

18 October 2017

17

Anders Svenningsson

1 reference

18 October 2017

7

Ralf Gold

1 reference

18 October 2017

Christoph Kleinschnitz

15

object named as

Christoph Kleinschnitz

1 reference

18 October 2017

21

Hayrettin Tumani

1 reference

18 October 2017

Clemens Warnke

1

1 reference

18 October 2017

Mark Stettner

2

1 reference

18 October 2017

Vera Lehmensiek

3

1 reference

18 October 2017

Thomas Dehmel

4

1 reference

18 October 2017

Anne K Mausberg

5

1 reference

18 October 2017

Gloria von Geldern

6

1 reference

18 October 2017

Reinhard Hohlfeld

9

1 reference

18 October 2017

Mathias Mäurer

10

1 reference

18 October 2017

Martin Stangel

11

1 reference

18 October 2017

Vera Straeten

12

1 reference

18 October 2017

Volker Limmroth

13

1 reference

18 October 2017

Thomas Weber

14

1 reference

18 October 2017

Mike P Wattjes

16

1 reference

18 October 2017

Tomas Olsson

18

1 reference

18 October 2017

Derik Hermsen

20

1 reference

18 October 2017

Ortwin Adams

22

1 reference

18 October 2017

12 November 2014

1 reference

Multiple Sclerosis Journal

18 October 2017

1 reference

18 October 2017

21

1 reference

18 October 2017

8

1 reference

18 October 2017

1036-1044

1 reference

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

18 October 2017

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Changes to anti-JCV antibody levels in a Swedish national MS cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Differential expression of cell adhesion molecules in the functional compartments of lymph nodes and tonsils

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

MiR-126: a novel route for natalizumab action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

Frequency and large T (LT) sequence of JC polyomavirus DNA in oligodendrocytes, astrocytes and granular cells in non-PML brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

α4Integrins as Therapeutic Targets in Autoimmune Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556296

21 January 2018

Identifiers

DOI

10.1177/1352458514556296

1 reference

18 October 2017

1 reference